Radioactive feeding tube in the palliation of esophageal malignant obstruction

Bi, Yonghua; Zhu, Xiaoyan; Yu, Zepeng; Jiao, Dechao; Yi, Mengfei; Han, Xinwei; Ren, Jianzhuang

doi:10.1007/s11547-020-01151-9

Cited by 9 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A clinical evaluation of the response is made with different imaging techniques (MRI, CT, and PET) and can classify the response according to the RECIST criteria [ 35 , 36 , 37 , 38 , 39 , 40 ]. With these premises, radiomic analysis has been used in this setting with the aim to predict the response of the neoadjuvant strategy [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment

Nardone

Boldrini

Grassi

et al. 2021

Cancers

View full text Add to dashboard Cite

Introduction: Neoadjuvant radiotherapy is currently used mainly in locally advanced rectal cancer and sarcoma and in a subset of non-small cell lung cancer and esophageal cancer, whereas in other diseases it is under investigation. The evaluation of the efficacy of the induction strategy is made possible by performing imaging investigations before and after the neoadjuvant therapy and is usually challenging. In the last decade, texture analysis (TA) has been developed to help the radiologist to quantify and identify the parameters related to tumor heterogeneity, which cannot be appreciated by the naked eye. The aim of this narrative is to review the impact of TA on the prediction of response to neoadjuvant radiotherapy and or chemoradiotherapy. Materials and Methods: Key references were derived from a PubMed query. Hand searching and ClinicalTrials.gov were also used. Results: This paper contains a narrative report and a critical discussion of radiomics approaches in different fields of neoadjuvant radiotherapy, including esophageal cancer, lung cancer, sarcoma, and rectal cancer. Conclusions: Radiomics can shed a light on the setting of neoadjuvant therapies that can be used to tailor subsequent approaches or even to avoid surgery in the future. At the same, these results need to be validated in prospective and multicenter trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment

Nardone

Boldrini

Grassi

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Было продемонстрировано, что использование назогастральных зондов для кормления, на которых были зафиксированы радиоактивные частицы и которые помещались в опухоль пищевода, является возможным методом обеспечения питания. Метод привел к значительному улучшению по сравнению с дооперационными данными [45].…”

Section: лучевая терапия внутрипросветная брахитерапияunclassified

Untitled

2021

КЭО

View full text Add to dashboard Cite

Республиканский специализированый научно-практический медицинский центр онкологии и радиологииАктуальность. Перспективным направлением лечения опухолей различной локализации является фотодинамической терапии (ФДТ), в которой экзогенные фотосенсибилизаторы применяются как инициаторы химической реакции в биологической ткани.Цель. Создание модели in vitro с использованием клеточных культур для изучения воздействия источником света с применением фиброволоконной оптики и фотосенсибилизатора -10% раствор 5-аминолевулиновая кислота.Материал и методы. Материалом служили изолированные клетки мышиной асцитной опухоли Эрлиха.Изолированные клетки мышиной асцитной опухоли Эрлиха в течении 3часов инкубировали с фотосенсибилизатором (5-аминолевулиновая кислота) при 37 0 С, затем облучали в течении 20 минут некогерентным источником света с длиной волны 660 нм. Для количественного учета цитотоксического действия, с помощью световой микроскопии под увеличением в 400 раз подсчитывали количество окрашенных раствором трипанового синего (погибших) клеток.Результаты. Анализ показал, что в результате воздействия некогерентным источником света с длиной волны 660 нм и фотосенсибилизатора (5-аминолевулиновая кислота) на клетки асцитной опухоли Эрлиха наблюдалась слабая токсическая реакция как при воздействии только фотосенсибилизатора и только облучения (27,0 + 4,5% и 16,0+3,7% соответственно). При воздействии совместно фотосенсибилизатора и облучения светом цитотоксическое действие было 62,0 + 4,9%, в контроле 21,0 + 4,1%( р<0,05).В результате воздействия некогерентным источником света с длиной волны 660 нм в течении 30 минут и фотосенсибилизатора (5-аминолевулиновая кислота) на клетки асцитной опухоли Эрлиха наблюдалась высокая цитотоксическая реакция (66,3% и 61,0% соответственно, в контроле 3,0 + 1,7% и 4,0 + 3,9%) в независимости от периода действия фотосенсибилизатора (3 и 20 часов).Ключевые слова: фотодинамическая терапия, фотосенсибилизатор ТАЖРИБАДА 660 НМ ТЎЛҚИН УЗУНЛИГИДАГИ ИЗЧИЛ БЎЛМАГАН ЁРУҒЛИК МАНБАИ ТАЪСИРИДА ФОТОДИНАМИК ТЕРАПИЯНИНГ САМАРАДОРЛИК ДАРАЖАСИНИ БАҲОЛАШ Долзарблиги: Фотодинамик терапия турли хил локализациядаги ўсмаларни даволашнинг истиқболли йўналиши бўлиб, экзоген фотосенсибилизаторлар биологик тўқималарда кимёвий реакцияларни инициатори сифатида қўлланилади.Мақсад: фотосенсибилизатор (5-аминолевулин кислотасининг 10% эритмаси) ва оптик толали оптика ёрдамида ёруғлик манбаи таъсирини ўрганиш учун ҳужайра култураларида in vitro моделини яратиш.Материал ва усуллар. Материал сифатида сичқонларнинг изоляцияланган асцит шаклида Эрлих ўсма штаммаларидан фойдаланилди. Сичқонларнинг изоляцияланган асцит шаклида Эрлих ўсма штаммалари 3 соат давомида 37 0 С да, фотосенсибилизатор (5-аминолевулин кислотасининг 10% эритмаси) билан инкубация қилинди ва 20 дақиқа давомида 660 нм тўлқин узунлигидаги изчил бўлмаган ёруғлик манбаи таъсирида нурлантирилди. Цитотоксик таъсирни миқдорий хисобини чиқариш учун трипан кўки эритмасида бўялган (нобуд бўлган) ҳужайраларни 400 баравар катталаштирилган ёруғлик микроскопи ёрдамида саналди....

show abstract

“…Approximately half of all patients with esophageal cancer are diagnosed in the middle and advanced stages of the disease, that is the stages in which tumors are not completely resectable (1); those patients often have a poor prognosis, with a low 5-year overall survival rate (2)(3)(4). Esophageal hemorrhage occurs in approximately 1%-5% of patients with advanced esophageal cancer, which is a big challenge (5).…”

Section: Introductionmentioning

confidence: 99%

Compression hemostasis using fully covered self-expandable metallic stents for refractory hemorrhages caused by esophageal cancer: A pilot study

Ren²,

Han³

2023

Front. Gastroenterol.

Self Cite

View full text Add to dashboard Cite

ObjectiveFully covered self-expandable metallic stents (SEMSs) have been widely used as a salvage therapy for patients with esophageal variceal bleeding. However, the role of fully covered SEMSs in the management of hemorrhage caused by esophageal cancer has not yet been established. We aimed to investigate the safety and efficacy of fully covered SEMSs as a salvage therapy for esophageal cancer-related hemorrhage.MethodsFrom September 2019 to March 2022, 17 patients, who underwent the insertion of fully covered SEMS for malignant esophageal hemorrhages, were retrospectively analyzed. Chest computed tomography (CT) scans and esophagographies were performed routinely to determine the location and length of the tumor. A fully covered SEMS was implanted under fluoroscopy. Baseline demographics were retrospectively collected, that is those for sex, age, previous treatment, comorbidities, lesion type, and stent size.ResultsA total of 20 metal stents were placed in 17 patients, with a technical success rate of 100% and a hemostasis success rate of 88.2%. Stent removal was performed in three patients because of complications. No perioperative deaths were related to stent placement or removal. Five main complications (29.4%) were found after stent insertion. Stent migration and restenosis were observed in two patients (11.8%). Except for two perioperative deaths and one patient lost to follow-up, all remaining 14 patients were successfully followed up. At the end of follow-up, two patients had survived without obvious symptoms, and a total of 12 patients were dead owing to tumor progression (n = 10), severe infection (n = 1), and cerebrovascular accident (n = 1). The median overall survival was 13.8 months.ConclusionInsertion of a fully covered SEMS may be a safe and effective means of the salvage management of refractory esophageal cancer-related hemorrhage, and its use in this context may lead to the development of innovative methods for compression hemostasis. However, further study with a larger sample size and comparison with other forms of salvage therapy.

show abstract

Radioactive feeding tube in the palliation of esophageal malignant obstruction

Cited by 9 publications

References 20 publications

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment

Untitled

Compression hemostasis using fully covered self-expandable metallic stents for refractory hemorrhages caused by esophageal cancer: A pilot study

Contact Info

Product

Resources

About